BN-50726

BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50=5.40 nM) . BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension) [1][2].

127279-06-5

12352005

Platelet-activating Factor Receptor (PAFR)

GPCR/G Protein

COVID-19-immunoregulation

Inflammation/Immunology; Cardiovascular Disease

CC1=NN=C2N1C3=C(C4=C(CN(S(=O)(CCCCCCCCCCCCCCCC)=O)CC4)S3)C(C5=CC=CC=C5Cl)=NC2

C34H48ClN5O2S2

658.36

[1]Zarco P, et al. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol. 1992 May;88 (2) :318-23.|[2]Yue TL, et al. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins. 1990 May;39 (5) :469-80.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19125/

Reference compound1

No Development Reported